Hemostemix Clarifies its October 3, 2023 News Release

2 years ago

Calgary, Alberta--(Newsfile Corp. - December 29, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")…

Sterling Urgent Care Acquires New Locations in Boise Area

2 years ago

Sterling Urgent Care Expands Reach in Boise with Four New Locations and Exciting Plans for a Fifth in Spring 2024BOISE,…

Report from the Extraordinary General Meeting of Promore Pharma AB Held on 29 December 2023

2 years ago

STOCKHOLM, SWEDEN / ACCESSWIRE / December 29, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) Promore Pharma AB, under change of name to…

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

2 years ago

HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the…

iZafe Group Receives Confirmed Order for 1,000 Dosell Units to the Netherlands

2 years ago

STOCKHOLM, SWEDEN / ACCESSWIRE / December 29, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces today that…

INSP Shareholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against Inspire Medical Systems, Inc.

2 years ago

SAN DIEGO--(BUSINESS WIRE)--$INSP #InspireMedicalSystemsInc--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons or…

VerityXR Strengthens Leadership Team with Appointment of Dr. Doug Nelson, PhD as Chief Architect and Engineer

2 years ago

CHICAGO, IL / ACCESSWIRE / December 28, 2023 / VerityXR, a trailblazer in Extended Reality (XR) healthcare technologies, is excited…

Establishment Labs to Present at the 42nd Annual J.P. Morgan Healthcare Conference

2 years ago

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…

NeoGenomics to Appeal Ruling

2 years ago

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services…

BriaCell Reports 71% Central Nervous System Response Rate in Advanced Breast Cancer Patients

2 years ago

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™,…